# Tempus AI (TEM) — News

TEM · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/tem/news

## Recent headlines

- [Tempus AI, Inc.: Canaccord Genuity raises target price to $95 from $80](https://www.ainvest.com/news/tempus-ai-canaccord-genuity-raises-target-price-95-80-2610) — AInvest Wire, Oct 12, 2026
  Canaccord Genuity has raised its price target for Tempus AI, Inc. (TEM) to $95 from $80, reflecting a more bullish outlook for the healthcare technology company. This adjustment aligns with recent developments, including the company’s first-quarter GAAP profitability, FDA approval for a key…
- [Tempus: To manage collection & transfer of tumor tissue & blood samples needed for next-generation sequencing](https://www.ainvest.com/news/tempus-manage-collection-transfer-tumor-tissue-blood-samples-needed-generation-sequencing-2610) — AInvest Wire, Oct 7, 2026
  Tempus, a company specializing in next-generation sequencing (NGS) for cancer research and diagnostics, plays a critical role in the collection and transfer of tumor tissue and blood samples required for genomic analysis. These samples are essential for generating comprehensive molecular profiles…
- [Tempus - Announces expanded multi-year collaboration for Intismeran autogene commercialization](https://www.ainvest.com/news/tempus-announces-expanded-multi-year-collaboration-intismeran-autogene-commercialization-2610) — AInvest Wire, Oct 7, 2026
- [Tempus - Financial terms of collaboration not disclosed](https://www.ainvest.com/news/tempus-financial-terms-collaboration-disclosed-2610) — AInvest Wire, Oct 7, 2026
- [Personalis, Inc. - HSR waiting period expired October 2, 2026 for Tempus AI merger - SEC filing](https://www.ainvest.com/news/personalis-hsr-waiting-period-expired-october-2-2026-tempus-ai-merger-sec-filing-2610) — AInvest Wire, Oct 6, 2026
  The Hart-Scott-Rodino (HSR) waiting period related to Tempus AI’s proposed acquisition of Personalis, Inc. expired on October 2, 2026, according to a recent SEC filing. This development marks a key procedural milestone in the merger process, indicating that regulatory scrutiny under the HSR Act has…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).